IUPAC_name = (2"S")-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methyl-
propanoic acid

CAS_number = 28860-95-9
ATC_prefix =
ATC_suffix =
ATC_supplemental =
PubChem = 34359
DrugBank = APRD00160
C=10 | H=14 | N=2 | O=4
molecular_weight = 226.229 g/mol
bioavailability =
protein_bound = 76%
metabolism = decarboxylated to dopamine in extracerebral tissues
elimination_half-life = 2 hours
excretion =
licence_EU =
licence_US = Carbidopa
pregnancy_AU =
pregnancy_US =
pregnancy_category =
legal_AU =
legal_UK = POM
legal_US =
legal_status =
routes_of_administration =

Carbidopa (MK-486, tradename Lodosyn) is a drug given to people with Parkinson's disease in order to inhibit peripheral metabolism of levodopa.

Carbidopa inhibits aromatic-L-amino-acid decarboxylase (DOPA Decarboxylase or DDC), an enzyme important in the biosynthesis of L-tryptophan to serotonin and in the biosynthesis of L-DOPA to Dopamine (DA). Along with carbidopa, other DDC inhibitors are benserazide (Ro-4-4602), difluromethyldopa, and α-methyldopa.

Used in tandem with L-DOPA (trade name levodopa, a dopamine precursor converted in the body to dopamine), it increases the plasma half-life of levodopa from 50 minutes to 1 1/2 hours. CarbiDOPA cannot cross the blood brain barrier, so it inhibits only peripheral DDC. It thus prevents the conversion of L-DOPA to dopamine peripherally. This reduces the side effects caused by dopamine on the periphery, as well as increasing the concentration of L-DOPA and dopamine in the brain.

The combination of carbidopa/levodopa) carries the brand names of Sinemet, Parcopa and Atamet; whilst Stalevo is a combination with entacapone, which enhances the bioavailability of carbidopa and levodopa.

Carbidopa is also used in combination with 5-HTP, a naturally occurring amino acid which is a precursor to the neurotransmitter serotonin and an intermediate in tryptophan metabolism. Carbidopa prevents 5-HTP's metabolism in the liver, which can lead to elevated levels of serotonin in the bloodstream. Research shows that co-administration of 5-HTP and carbidopa greatly increases plasma 5-HTP levels.

External links

* [ Lodosyn prescribing information]
* [ Sinemet datasheet for New Zealand]

Wikimedia Foundation. 2010.

Look at other dictionaries:

  • carbidopa — inhibidor de la decarboxilasa que no atraviesa la barrera hematoencefálica y, por tanto, solo actúa periféricamente. Se utiliza en el tratamiento de la enfermedad de Parkinson, conjuntamente con la levodopa estructura química [véase… …   Diccionario médico

  • Carbidopa — Strukturformel Allgemeines Freiname Carbidopa Andere Namen …   Deutsch Wikipedia

  • carbidopa — A dopa decarboxylase inhibitor which does not enter the brain used in conjunction with levodopa in the treatment of Parkinson disease to reduce L dopa doses and reduce side effect s. * * * car·bi·do·pa …   Medical dictionary

  • carbidopa — n.; see levodopa …   The new mediacal dictionary

  • Carbidopa/levodopa — Combination of Agonist Levodopa Enzyme inhibitor Carbidopa Clinical data MedlinePlus a601068 …   Wikipedia

  • 5-Hydroxytryptophan — Not to be confused with serotonin (5 hydroxytryptamine, 5 HT). 5 Hydroxytryptophan …   Wikipedia

  • Entacapone — Systematic (IUPAC) name (2E) 2 cyano 3 (3,4 dihydroxy 5 nitrophenyl) N,N diethylprop 2 enamide Clinical data Trade names …   Wikipedia

  • Parkinsonmittel — sind Arzneimittel, die zur Behandlung der Parkinson Krankheit verwendet werden. Die Parkinson Krankheit ist dadurch charakterisiert, dass es in den Basalganglien des Gehirns einen relativen Mangel an Dopamin gibt, der durch das Absterben… …   Deutsch Wikipedia

  • L-dopa — Nombre (IUPAC) sistemático …   Wikipedia Español

  • 5-Hidroxitriptófano — Esta página o sección está siendo traducida del idioma inglés a partir del artículo 5 hydroxytryptophan, razón por la cual puede haber lagunas de contenidos, errores sintácticos o escritos sin traducir. Puedes colaborar con Wikipedia …   Wikipedia Español

Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”

We are using cookies for the best presentation of our site. Continuing to use this site, you agree with this.